ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -4 مورد

Impact of the addition of carboplatin to neoadjuvant chemotherapy on pathologic complete response and event-free/disease-free survival in triple-negative breast cancer

Impact of the addition of carboplatin to neoadjuvant chemotherapy on pathologic complete response and event-free/disease-free survival in triple-negative breast cancer
Study Regimens Number of patients pCR rates (%) EFS/DFS (%)
BrighTNess[1,2] Weekly paclitaxel followed by doxorubicin and cyclophosphamide 158 31 69 EFS at 4 years
Weekly paclitaxel with every-three-week carboplatin followed by doxorubicin and cyclophosphamide 160 58* 79*
Weekly paclitaxel with every-three-week carboplatin and veliparib followed by doxorubicin and cyclophosphamide 316 53* 78*
GeparSixto[3,4] Weekly paclitaxel with weekly non-pegylated liposomal doxorubicin and every-three-week bevacizumab 157 43 76 DFS at 3 years
Weekly paclitaxel with weekly non-pegylated liposomal doxorubicin, weekly carboplatin and every-three-week bevacizumab 158 57* 86*
CALGB/Alliance 40603[5-7] Weekly paclitaxel followed by doxorubicin and cyclophosphamide with or without every-three-week bevacizumab 212 41 70 EFS at 5 years
Weekly paclitaxel and every-three-week carboplatin followed by doxorubicin and cyclophosphamide with or without every-three-week bevacizumab 221 54* 70
Gupta, et al.[8] Weekly paclitaxel followed by doxorubicin and cyclophosphamide or epirubicin and cyclophosphamide 356 40 64 EFS at 5 years
Weekly paclitaxel and carboplatin followed by doxorubicin and cyclophosphamide or epirubicin and cyclophosphamide 361 54* 71
PEARLY[9] Doxorubicin and cyclophosphamide followed by weekly paclitaxel or every-three-week docetaxel 434 39 75 EFS at 5 years
Doxorubicin and cyclophosphamide followed by every-three-week carboplatin with either weekly paclitaxel or every-three-week docetaxel 434 46 82*

DFS: disease-free survival; EFS: event-free survival; pCR: pathologic complete response (ypT0/isN0).

* Denotes a statistically significant difference when compared against the study arm without carboplatin.

¶ In this trial approximately 70% of patients were treated in the neoadjuvant setting versus 30% in the adjuvant setting.

References:
  1. Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): A randomised, phase 3 trial. Lancet Oncol 2018; 19:497.
  2. Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol 2022; 33:384.
  3. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014; 15:747.
  4. Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol 2018; 29:2341.
  5. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13.
  6. Sikov WM, Polley M-Y, Twohy E, et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). J Clin Oncol 2019; 37:591.
  7. Shepherd JH, Ballman K, Polley MC, et al. CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. J Clin Oncol 2022; 40:1323.
  8. Gupta S, Nair NS, Hawaldar R, et al. Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial. Cancer Res 2023; 83:GS5-01.
  9. Sohn J, Kim GM, Jung KH, et al. A randomized, multicenter open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR-1 PEARLY trial. J Clin Oncol 2024; 42:LBA502.
Graphic 147004 Version 1.0